Product Center
The Launch Meeting of the Phase III Clinical Trial of the Quadrivalent Influenza Virus Subunit Vaccine (Ages 6–35 Months) Was Successfully Completed
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-02-04
- Views:
(Summary description)As the old year concludes with splendid achievements, the new year begins with renewed progress! On January 31st, the kick-off meeting for the Phase III clinical trial of Ab&B Bio-Tech Co., Ltd. JS’s quadrivalent influenza virus subunit vaccine (ages 6–35 months) was held at the Henan clinical research site. This marks another Phase III clinical trial following the successful completion of the quadrivalent influenza virus subunit vaccine (ages 3 and above) Phase III trial.
The Launch Meeting of the Phase III Clinical Trial of the Quadrivalent Influenza Virus Subunit Vaccine (Ages 6–35 Months) Was Successfully Completed
(Summary description)As the old year concludes with splendid achievements, the new year begins with renewed progress! On January 31st, the kick-off meeting for the Phase III clinical trial of Ab&B Bio-Tech Co., Ltd. JS’s quadrivalent influenza virus subunit vaccine (ages 6–35 months) was held at the Henan clinical research site. This marks another Phase III clinical trial following the successful completion of the quadrivalent influenza virus subunit vaccine (ages 3 and above) Phase III trial.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-02-04 16:17
- Views:
As the old year concludes with splendid achievements, the new year begins with renewed progress! On January 31st, the kick-off meeting for the Phase III clinical trial of Ab&B Bio-Tech Co., Ltd. JS’s quadrivalent influenza virus subunit vaccine (ages 6–35 months) was held at the Henan clinical research site. This marks another Phase III clinical trial following the successful completion of the quadrivalent influenza virus subunit vaccine (ages 3 and above) Phase III trial.
This clinical trial is a randomized, blinded, active-controlled Phase III study to evaluate the safety and immunogenicity of the quadrivalent influenza virus subunit vaccine in healthy participants aged 6–35 months. The objective is to verify the efficacy and safety of the vaccine in this pediatric population.Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
